CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

The chief executive of the company behind Ozempic and Wegovy blamed insurers and middlemen for the high costs of weight-loss ...

When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit ...

Bipartisan lawmakers grilled Novo Nordisk CEO Lars Fruergaard Jørgensen in a Senate hearing in an attempt to pick apart the ...

Novo Nordisk CEO Lars Fruergaard Jørgensen defended the prices of his company’s megablockbuster obesity and Type 2 diabetes ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on ...

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...